Zentalis Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Zentalis Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to 2023.
  • Zentalis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $12.7M, a 4.73% decline year-over-year.
  • Zentalis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $53.3M, a 13.4% increase year-over-year.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $54.8M, a 17% increase from 2022.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $46.8M, a 31.1% increase from 2021.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $35.7M, a 54.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $54.8M +$7.98M +17% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $46.8M +$11.1M +31.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $35.7M +$12.6M +54.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $23.1M +$22.5M +3651% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 $617K Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.